Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc.

Overview
Date Founded

2006

Headquarters

65 Hayden Avenue,Suite 3000N,Lexington, MA 02421

Type of Company

Public

Employees (Worldwide)

71

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Contact Data
Trying to get in touch with decision makers at Concert Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chairman of the Board, Co-Founder

Chief Financial & Accounting Officer

Chief Operating Officer

Senior Vice President & Chief Development Officer

Chief Legal Officer & Secretary

Senior Vice President-Legal Affairs

Senior Director

Senior Director of Development

Senior Director

Board of Directors

Chairman of the Board, Co-Founder at Concert Pharmaceuticals, Inc.

Co-Founder at Concert Pharmaceuticals, Inc.

Professor at Harvard University

Co-Founder at Three Arch Partners

Managing Partner at Bio Point Group LLC

Global Chief Commercial Officer at Ascendis Pharma A/S

Treasurer & Trustee at Kieve Affective Education, Inc.

Founder at XenoPort, Inc.

Paths to Concert Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Concert Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Ingalls & Snyder manages and advises pension plans, philanthropic and educational endowments, corporations and an open-end growth mutual fund. The firm is a multi-cap value manager. They use bottom-up research to examine balance sheets valuations and possible risk/return ratios. Ingalls & Snyder generally recommends a long-term, total-return strategy. The firm prefers investments in securities with an established trading history. They rarely participate in initial public offerings. Ingalls & Snyder conducts in-house research, including internally generated forecasts of ROE for the stocks they follow. Analysts contribute to the sellside as well as the buyside. The firm's portfolio managers develop their own investment philosophies dependent on client objectives. Their Legacy Growth fund invests in a well-diversified portfolio of growth-oriented equities. Their objective is to achieve above average long-term growth of capital for shareholders. The majority of the fund's holdings are in large-cap common stocks, the remainder being in shares of medium and small-sized companies. The fund seeks companies having strong underlying financial characteristics and prospects for sustained above average growth in earnings. Ingalls & Snyder's taxable fixed-income department emphasizes high yield securities. They specialize in little-known and smaller-sized issues. They also provide facilities to transact in US Government securities, municipal securities and options contracts.

Details Hidden

L1 Capital is a style neutral manager which recognizes the equal importance of both value and quality in investing. The investment team conducts detailed fundamental, bottom-up stock research to utilize investment process. The firm invests in high quality businesses trading well below their intrinsic value. Their investment process combines discounted cash flow valuation with qualitative considerations such as management quality, industry & company structure and business trends to identify attractive investment opportunities. The core of the investment approach is a high level of interaction with a wide range of market participants.

Details Hidden

Corriente Advisors invests in the public equity and alternative investment markets in the US. The firm employs a combination of in-house and external research to construct its portfolios.

Recent Transactions
Details Hidden

Concert Pharmaceuticals, Inc. issued . USD Common Stock

Details Hidden

Concert Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Concert Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onConcert Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onConcert Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onConcert Pharmaceuticals, Inc. issued . USD Common Stock

Director

Advised onConcert Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onConcert Pharmaceuticals, Inc. issued . USD Common Stock

Legal Advisor

Advised onConcert Pharmaceuticals, Inc. issued . USD Common Stock

Advisors & Consultants
Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Consultant

Chief Financial Officer at Obsidian Therapeutics, Inc.

Clients

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Key Stats and Financials As of 2020
Market Capitalization
$215M
Total Enterprise Value
$278M
Earnings Per Share
$-2.4
Revenue
$7.9M
EBITDAMargin
-895.44%
Enterprise Value / Sales
35.24x
TEVNet Income
-3.72x
Debt TEV
0.06x
Net Profit
$-74.8M
Total Debt
$16M
EBITDA
$-70.8M
Total Equity
$131M
Three Year Compounded Annual Growth Rate Of Revenue
-61.99%
Non-Profit Donations & Grants
Investors
Details Hidden

Price Associates uses a complex and multifaceted approach to investment analysis and asset management decisions. They integrate ESG factors into their investment research process. The firm focuses on the ESG factors they consider most likely to have a material impact on the performance of securities in client accounts. Price Associates also focuses on their analytical process on three areas of research: the industry, the contracts issued, and the creditworthiness of each individual issuer.

Details Hidden

Indian Bank engages in the provision of banking products and services. It operates through the following segments: Treasury, Corporate/Wholesale Banking, Retail Banking and Other Banking Operations. It offers NRI-Foreign Exchange, Applications Supported by Blocked Amount for IPO, wealth management services, supreme current accounts, educational loan, centralized pension processing, interest subsidy for educational loans, and financial inclusion plan. The company was founded by V. Krishnaswamy Iyer on March 5, 1907 and is headquartered in Chennai, India.

Details Hidden

Jennison Associates has expertise in a range of equity strategies across styles and market-caps, as well as fixed income strategies. The firm manages portfolios based on internal fundamental research, bottom-up security selection and a highly interactive investment process. They offer select capabilities in the following investment disciplines: Growth Equity, Opportunistic Equity, Small and Mid-Cap Equity, Global Equity, Value Equity, Income & Infrastructure Equity and Fixed Income. Additionally, Jennison Associates offers Custom Solutions, Combination Strategies and Sector Strategies. Jennison Associates specializes in fundamental analysis, which involves attempting to gain insight into the future value of a company by studying company-specific and market-related quantitative (such as financial statements) and qualitative (such as quality of company management or products) information.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Eli Lilly & Company Pharmaceuticals

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Incyte Corp. Pharmaceuticals - Wilmington, DE

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Concert Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Concert Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Concert Pharmaceuticals, Inc..